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Abstract
Background: Appropriate protein subcellular localization is essential for proper cellular function. Central to the
regulation of protein localization are protein targeting motifs, stretches of amino acids serving as guides for protein
entry in a specific cellular compartment. While the use of protein targeting motifs is modulated in a post-translational
manner, mainly by protein conformational changes and post-translational modifications, the presence of these motifs
in proteins can also be regulated in a pre-translational manner. Here, we investigate the extent of pre-translational
regulation of the main signals controlling nucleo-cytoplasmic traffic: the nuclear localization signal (NLS) and the
nuclear export signal (NES).
Results: Motif databases and manual curation of the literature allowed the identification of 175 experimentally validated
NLSs and 120 experimentally validated NESs in human. Following mapping onto annotated transcripts, these motifs were
found to be modular, most (73 % for NLS and 88 % for NES) being encoded entirely in only one exon. The presence of a
majority of these motifs is regulated in an alternative manner at the transcript level (61 % for NLS and 72 % for NES) while
the remaining motifs are present in all coding isoforms of their encoding gene. NLSs and NESs are pre-translationally
regulated using four main mechanisms: alternative transcription/translation initiation, alternative translation termination,
alternative splicing of the exon encoding the motif and frameshift, the first two being by far the most prevalent
mechanisms. Quantitative analysis of the presence of these motifs using RNA-seq data indicates that inclusion of these
motifs can be regulated in a tissue-specific and a combinatorial manner, can be altered in disease states in a directed way
and that alternative inclusion of these motifs is often used by proteins with diverse interactors and roles in diverse
pathways, such as kinases.
Conclusions: The pre-translational regulation of the inclusion of protein targeting motifs is a prominent and
tightly-regulated mechanism that adds another layer in the control of protein subcellular localization.
Keywords: Protein targeting motifs, Nuclear localization signal, Nuclear export sequence, Alternative splicing,
Pre-translational regulation, Protein subcellular localization, RNA-seq, Tissue-specific regulation
Background
Protein subcellular localization requires tight and timely
regulation, to ensure proper environment and interaction
partners, and ultimately function [1]. Localization regula-
tion is achieved through diverse mechanisms which can
act sequentially, combinatorially or competitively, the inte-
gration of which determines the localization distribution
of proteins in the cell. In addition, protein localization is
often dynamic, and mechanisms exist to allow transloca-
tion of proteins to respond to diverse changes in the cell
and its environment.
Protein targeting motifs have been identified for all main
eukaryotic cellular compartments and represent a highly
prevalent mechanism regulating protein localization [2–5].
Targeting motifs typically involve short linear sequences of
3 to 30 amino acids, often found at protein ends or in ac-
cessible and/or disordered regions [6, 7]. The first targeting
motifs that were described, over thirty years ago, were the
signal peptide and the nuclear localization signal (NLS),
specifying respectively entry into the secretory pathway
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through the endoplasmic reticulum, and targeting to the
nucleus [8, 9]. In addition to targeting motifs, post-
translational modifications (PTMs) are also often involved,
either to modulate the accessibility of targeting motifs [10],
to serve as a sorting signal [11, 12], or to anchor proteins in
membranes by the addition of lipid chains [13, 14]. Other
characterized mechanisms for the regulation of protein
localization include targeting or more often retention
through interactors which can include proteins, lipids and
nucleic acid chains through the use of interaction domains
[15–17]. Protein localization often results from the integra-
tion, in the proper order, of several of these mechanisms.
The regulation of translocation across the nuclear enve-
lope has been particularly well characterized. Targeting to
the nucleus from the cytoplasm typically involves NLSs,
several classes of which have been described. Classical
NLSs, the first to be identified, are short motifs involving
basic residues, and can be divided into two main groups
[18, 19]. Monopartite NLSs consist of a stretch of three to
four basic residues [9, 18, 20] while bipartite NLSs are com-
posed of two segments of basic residues separated by a
linker of 10 to 12 residues [18]. Classical NLSs are recog-
nized by Kapα-Kapβ1 importin heterodimers, of the karyo-
pherin superfamily, for translocation across the nuclear
pore complex and into the nucleus [19]. Many non-classical
and more diverse NLSs have also been described, including
combinations of polar/charged and non-polar residues [3,
21, 22]. More recently, longer nuclear targeting motifs rec-
ognized by the karyopherin Kapβ2 and averaging between
20 and 30 residues in length were described [23]. These PY-
NLSs (Proline-Tyrosine Nuclear Localization Signals), un-
like the classical NLS, do not have a strong consensus for
their motifs, which are composed of a hydrophobic or basic
N-terminal region and a C-terminal RX2-5PY motif [24].
Nuclear export sequences (NESs), specifying transloca-
tion from the nucleus to the cytoplasm have also been
extensively characterized [25]. NESs are short motifs
typically containing four hydrophobic residues, and most
often leucines, separated by a small number of spacing
residues [26]. NESs are also recognized by a member of
the karyopherin superfamily of transport receptors, the
CRM1 exportin, for export to the cytoplasm [25].
While the use of NLSs and NESs for nucleocytoplas-
mic transport is prevalent, some nuclear proteins do not
contain these signals [20, 27]. Several such proteins em-
ploy other strategies to shuttle to and from the nucleus
(for example by piggy-back onto other proteins that do
contain NLSs [27–29]) but for most, targeting mecha-
nisms are currently unknown [20]. NLSs and NESs are
often regulated by PTMs, and their accessibility can also
be regulated by conformational change, allowing a dy-
namic control of their usage [30, 31].
In addition to the post-translational regulation of protein
localization mentioned above, the targeting of proteins can
also be regulated through pre-translational mechanisms,
adding another level of complexity in the control of subcel-
lular localization. In particular, the inclusion of targeting
motifs in transcripts can be regulated by different types of
pre-translational mechanisms. As illustrated in Fig. 1, alter-
native transcription/translation initiation sites, alternative
splicing of the motif-encoding exon, alternative translation
ends and coding frameshifts can all lead to protein iso-
forms encoded by the same gene but differing in the pres-
ence of targeting motifs [32–34]. Many different studies of
individual genes have made light of such mechanisms
which lead to the targeting of encoded proteins to more
than one compartment. In particular, the subcellular distri-
bution of many enzymes reflects the differential presence
of mitochondrial targeting sequences or peroxisomal tar-
geting sequences, as regulated at the pre-translational level
[32–34]. On a transcriptome-wide level, the differential use
of signal peptides and transmembrane domains as regu-
lated at the pre-translational level has been investigated in
mouse by considering all transcripts defined by the RIKEN
FANTOM3 project [35, 36]. Similarly, the pre-translational
regulation of short linear motifs, including short protein
targeting motifs, has been characterized and classified by
the Gibson group (for example, [37–39]). Collectively,
these studies show that pre-translational regulation mecha-
nisms represent an important and widely-used level of
regulation of the inclusion of protein targeting motifs and
ultimately of protein subcellular localization. However, the
dynamic and diverse cellular roles of this type of regulation,
have not been extensively and systematically investigated.
Here, we investigate of the extent of regulation of pro-
tein localization at the pre-translational level, through the
study of targeting motif inclusion in transcripts, using the
NLS and NES as model signals. The transcriptome-wide
characterization of these targeting motifs reveals that 39 %
of NLSs are constitutive in the sense that they are present
in all coding isoforms of their encoding gene. The
remaining 61 % of NLSs are considered to be alternatively
regulated as they are not present in all coding transcripts
of the same gene. In the case of NESs, 72 % are alternative.
The inclusion of most alternative NLSs and NESs is regu-
lated by alternative translation initiation and termination,
although direct alternative splicing of the exon encoding
the motif is also an important mechanism. The analysis of
different deep-sequencing datasets in human indicates
that the regulation of the inclusion of these targeting
motifs at a pre-translational level can be dynamic and
vary according to tissue-type, is more prominently used
by proteins with diverse interactors, can be tightly reg-
ulated in a combinatorial way, and can be deregulated
in disease states. Collectively, our findings show evi-
dence of extensive and tightly-regulated use of pre-
translational regulation mechanisms for the inclusion
of the NLSs and NESs.
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Results
Distribution of NLSs and NESs in transcripts/proteins
To characterize the extent of regulation of motif inclusion
at a pre-translational level, we began by extensively curat-
ing the literature and public databases for experimentally
validated human NLSs and NESs, as described in the
Methods section. In doing so, we identified 175 NLSs
present in 165 genes, and 120 NESs present in 102 genes
as listed in Additional file 1. All NLSs and NESs were
mapped onto the corresponding transcript and protein se-
quences and to the appropriate encoding exons using the
hg38 assembly of the human genome and Ensembl anno-
tations [40] as described in the Methods section. Analysis


















Alternative motif inclusion due to alternative promoter and/or alternative translation initiation:
Alternative motif inclusion due to alternative translation termination:
Alternative motif inclusion due to alternative splicing of the exon containing the motif: 
Alternative motif inclusion due to alternative coding frame usage:
Fig. 1 Modes of pre-translational regulation of the inclusion of protein targeting motifs. Four general mechanisms can regulate the inclusion of
protein targeting motifs at the pre-translational level. The use of alternative promoters and/or alternative start codons can lead to different N-terminal
protein ends differing in the presence of a targeting signal (a). Similarly, different C-terminal ends, which can be caused by alternative translation
termination (b), can result in differential motif inclusion. Differential splicing of the exon containing the targeting motif (in this case, a cassette
exon), can cause alternative motif inclusion (c). Alternative splicing can also result in a coding frameshift affecting the presence of a targeting
motif (d). While alternative splicing can directly affect motif inclusion causing the motif to be spliced in or out (c), it can also indirectly regulate motif
inclusion by affecting translation initiation (a) or termination (b), or by changing the coding frame (d). Start and stop codons are indicated respectively
with green and red arrowheads, targeting motifs are shown as pink rectangles, exons are represented as boxes and introns as lines
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NLSs are entirely encoded in only one exon, while for
NESs, the proportion goes up to 88 % (Fig. 2a). The differ-
ence between NLSs and NESs can be explained in part by
the fact that NLSs are on average longer than NESs, mak-
ing them more likely to be encoded on more than one exon
(Fig. 2b). However, when compared to randomly chosen
protein subsequences of the same length distribution as the
respective motifs, significantly more NESs, but not NLSs,
are entirely encoded in one exon than expected by chance
(p-value = 0.03 for NES vs 0.9 for NLS), suggesting that
NESs are under pressure to remain modular in terms of al-
ternative inclusion potential. In addition, some of these mo-
tifs are present on small exons that seem to have appeared
solely for the conditional inclusion of the motif, as dis-
cussed with specific examples in following sections.
The position of NLSs and NESs in protein sequences
might also influence how the motif is regulated at a pre-
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Fig. 2 The positions of protein targeting motifs within genes and proteins are not uniformly distributed. a Most NLSs and NESs are entirely contained
in only one exon. b Length distributions of NLSs and NESs. While NESs are represented by a unimodal length distribution, NLSs are characterized by a
multimodal distribution, reflecting the diverse types of NLSs (monopartite, bipartite, PY-NLS) that have been described and that are considered in this
study. c Distribution of the position of NLSs and NESs in proteins. d The majority of NLS and NES are regulated in an alternative manner
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can be present throughout the protein and do not have
strong preferences for protein ends. Positioning of mo-
tifs in the protein will influence the modes of regulation
used to control motif inclusion. To investigate this, we
set out to classify and characterize the prevalence of
mechanisms regulating the presence of these motifs in
transcripts from all genes containing them.
Alternative regulation of the inclusion of NLSs and NESs
To investigate the distribution of the presence of motifs
for all genes containing NLSs and NESs, we considered
all coding transcripts defined in the Ensembl database
[40] for assembly hg38 of the human genome, as de-
scribed in the Methods. In total, 39 % (68/175) of NLSs
and 28 % (34/120) of NESs are present in all coding
transcripts of their encoding gene, and are referred to as
constitutive motifs (Fig. 2d). The remaining motifs are
alternative in the sense that not all coding transcripts of
the encoding genes contain the motif. An example of
constitutive motifs is shown in Fig. 3a: the FOXO3 NLS
and NES are both contained in an exon present in all 3
transcripts of the gene.
Of the modes of pre-translational differential regula-
tion of targeting motif inclusion previously observed
[32–34] and summarized in Fig. 1, examples of each type
were identified in the regulation of NLSs and NESs.
While cassette exons are the most common type of al-
ternative splicing mechanisms regulating exons contain-
ing NLSs and NESs, we also observe alternative 5′/3′
splice sites and an exonic intron as shown in Fig. 3 b-e.
However, the most prevalent mechanisms of alternative
regulation of NLS and NES inclusion are the alternative
translation initiation and termination sites, which result
in proteins with different N-termini and C-termini re-
spectively, as shown in Fig. 4. For example, 5 isoforms of
the SMAD3 gene are defined in the Ensembl annota-
tions, all differing in their N-termini due to the usage of
different promoters, and as a consequence, different
start codons. Only the longest isoform has the NLS,
right at its N-terminal extremity (Fig. 4a). Similarly, the
presence of the MIER1 NES is alternatively regulated as
several coding transcripts start downstream of the exon
encoding the motif. The MIER1 NES is an example of a
motif regulated by several pre-translational mechanisms
as this motif is encoded in a cassette exon and is thus
regulated by both alternative splicing and alternative
transcription/translation initiation (Fig.4b). The presence
of the BIRC5 NES is also regulated by more than one
mechanism as not only are there two coding transcripts
that end before the beginning of the motif, but alterna-
tive splicing of upstream exons causes a frameshift of
the exon encoding the NES in one coding transcript
(Fig. 4c,d). We note that alternative translation initia-
tions and terminations, as well as frameshifts, are often
indirectly caused by alternative splicing of upstream
exons (see for example some transcripts in Fig. 4c, d).
Thus alternative splicing, whether directly of the exon
encoding the motif, or of exons further upstream, is a
central mechanism in the pre-translational regulation of
protein targeting motif inclusion. The regulation modes
found for each motif are indicated in Additional file 2
for NLSs and Additional file 3 for NESs.
To determine the extent of usage of the different pre-
translational regulation mechanisms observed and defined
in Fig. 1, we classified all NLSs and NESs considered (listed
in Additional file 1) according to their regulation modes
(as shown in Fig. 5a). While the inclusion of 25 % and 21 %
of alternative NLSs and NESs respectively are directly reg-
ulated by alternative splicing, a much larger proportion, in
fact almost all alternative NLSs (95 %) and alternative
NESs (99 %) are regulated by alternative initiation and/or
alternative end. Alternative initiation and termination were
previously found to be predominant regulatory mecha-
nisms for the inclusion of signal peptides and transmem-
brane domains [35, 36]. A subset of alternative NLSs and
NESs (36 % for both NLSs and NESs) are regulated by
more than one mechanism (for example, Fig. 4b-d). Thus
the pre-translational regulation of NLS and NES inclusion
is widespread and uses several distinct mechanisms, often
tightly regulating the inclusion of the motif with little extra
flanking sequence (for example Figs. 3c, 4).
We investigated the distribution of the number of cod-
ing transcripts containing an NLS or NES constitutively
or alternatively. Interestingly, alternative NLSs and NESs
are found in genes encoding significantly more transcripts
than those containing constitutive NLSs and NESs (Fig. 5b,
p-value < 6.3*10−6 for NES and p-value < 5.2*10−12 for
NLS using the two sample Kolmogorov-Smirnov test) in-
dicating that genes containing such alternative motifs en-
code on average a larger and more diverse set of proteins
than genes containing constitutive motifs and that the
regulation of motif inclusion is responsible for some of
the need for co- and post-transcriptional regulation, as
previously shown for signal peptides and transmembrane
domains [35, 36].
When NLSs are classified according to their subtype
as described in the Methods, PY-NLSs are found to be
the most regulated in an alternative manner and most
likely to be present in more than one exon (67 % of PY-
NLSs are alternative and 38 % are encoded in 2 exons;
Additional file 4: Figure S1). Unlike monopartite NLSs,
bipartite NLSs and non-classified NLSs which are two to
four times more likely to be regulated by alternative
translation initiation and termination than by splicing,
PY-NLSs display equal counts for these three types of
regulation (Additional file 4: Figure S1). Thus the diverse
group of PY-NLS stands out as the most alternatively
regulated subgroup of NLSs.
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Quantitative analysis of motif inclusion across normal
human tissues
The above analysis considers all coding transcripts de-
fined in the Ensembl database for a given gene. However,
the relative cellular abundance of the transcripts with
the motif compared to the transcripts without the motif
is undefined in the above analysis. We note that for a
gene containing an alternatively regulated motif as de-
fined above, if all its transcripts lacking the motif are
expressed at very low level, such an ‘alternative’ motif
will in fact behave like a constitutive motif when quanti-
fied and when used in the cell. To estimate the true level
Fig. 3 Examples of constitutive and alternative splicing-regulated NLSs and NESs. Screenshots of the UCSC Genome Browser displaying portions
of transcripts encoding protein targeting motifs. NLSs and NESs are represented by red and blue blocks respectively, in the Motifs track.
The Comprehensive Gene Annotation Set from GENCODE Version 23 (Ensembl 81) track shows the position of exons (blocks) and introns
(lines with arrows showing direction of transcription) in the chromosome window considered. Coding exons are represented by thick blocks whereas
non-coding exons (UTRs or non-coding transcripts) are represented by thin blocks. a Constitutive NLS and NES in FOXO3 gene. b FHL1 cassette exon
containing NES and NLS. c Cassette exon of CTNND1 gene, containing NES. d MIER1 NLS encoded in exon regulated by alternative 5′ splice site. e
RELA NES encoded in portion of exon that can be spliced out (intronic exon)
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of motif inclusion in transcriptomes, we analysed RNA-
seq data from the Illumina Human Body Map project
(NCBI GEO accession GSE30611), which provides data
for 16 normal human tissues. As described in the
Methods section, to quantify motif inclusion, we define
the motif inclusion index (MII), which represents the
relative abundance of all coding transcripts containing
the motif out of all coding transcripts from the gene.
The MII thus ranges between 0 and 1, 0 representing
motifs for which out of all coding transcripts produced
by the encoding gene, only those not containing the
motif are detected, while an MII of 1 is calculated for
motifs for which all coding transcripts produced by the
encoding gene contain the motif. Out of the 165 and
102 genes containing NLSs and NESs respectively ac-
cording to our above analysis of the transcripts from the
Ensembl database, 142 and 91 of these genes were de-
tected above a set cut-off (total abundance of the gene
of at least 1 transcript per million (TPM) in at least 9 of
the 16 tissues considered) and the other genes were not
further considered. Unsurprisingly, all NLSs and NESs
classified above as constitutive obtain MII values of 1.
MII of both alternative NLS and alternative NES cover
the whole range between 0 and 1. Approximately 10 %
of NLSs and NESs (15 NLSs and 8 NESs) that we classi-
fied as alternative according to the Ensembl transcripts
definitions obtain MII values above 0.95 for all human
tissues with RNA-seq data available in this dataset, and
were considered to be regulated like constitutive motifs.
While we cannot exclude that these motifs might be al-
ternatively included in transcripts in other tissue types





Fig. 4 Examples of alternative NLSs and NESs regulated by alternative transcription/translation initiation or termination. Screenshots of UCSC Genome
Browser as described in Fig. 3. a SMAD3 NLS regulated by alternative transcription and alternative initiation. b The MIER1 NES is encoded in a cassette
exon and its inclusion is also regulated by alternative transcription and alternative initiation (some transcripts, highlighted in a pink box, start at a
downstream exon). c The BIRC5 NES inclusion is regulated by alternative transcription and translation end (some transcripts end before the exon
containing the targeting motif) and by a frameshift (visible in panel d, which represents a zoomed-in section of panel c)
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evidence of their alternative regulation at appreciable
levels. The inclusion indexes of the remaining NLSs and
NESs with MII values below 0.95 in at least one tissue
(alternative motifs as defined by RNA-seq analysis) are
shown in Figs. 6 and 7. For both alternative NESs and al-
ternative NLSs, a small subset of genes have either uni-
formly high MII or uniformly low MII, but the majority
have variable MII values across tissues, showing tissue-
specificity in the regulation of the inclusion of these motifs.
For example, the PRKD2 NES MII goes from around 0.40
in testes to above 0.80 in brain and white blood cells and as
high as 1.0 in liver tissue (Fig. 7), while the BAG6 NLS MII
ranges from below 0.15 in breast and brain tissue to above
0.90 in the liver, lung, testes, prostate, kidney and lymph
nodes (Fig. 6). PRKD2 (protein kinase D2) is a member of
the PKD family of serine/threonine kinases that mediate sig-
nals from diverse pathways including T-cell receptor, G-
protein-coupled receptor and MAPK signaling pathways
and can activate the NF-kB pathway following stress signals
[41–43]. PRKD2 is found both in the nucleus and the cyto-
plasm [42, 44] and has many interactors and substrates (for
example [41–43]). In the nervous system, PRKD2 plays an
essential role in the establishment and maintenance of neur-
onal polarity through activity at the Golgi apparatus [45, 46],
supporting the need for a high NES MII value in brain. The
differential inclusion of the PRKD2 NES thus likely reflects
its diverse cellular functions and interactors in different tis-
sues. Similarly, BAG6 is also found in both the nucleus and
cytoplasm and is involved in diverse functions in both these
compartments, including serving as a chaperone for the in-
sertion of tail-anchored proteins at the endoplasmic
reticulum and playing a role in DNA damage induced apop-
tosis in the nucleus through the acetylation of p53 [47–49].
In testes, BAG6 has been characterized as a nuclear protein
involved in the regulation of chromatin structure and gene
expression through the recruitment of histone modifiers
[50], supporting the high NLS MII found for BAG6 in testes.
In contrast, other studies find BAG6 mainly in the cyto-
plasm, playing a role in the proteasomal degradation of mis-
folded proteins during endoplasmic reticulum-associated
degradation (ERAD) by maintaining polypeptides in soluble
states [51, 52]. As in the case of PRKD2, the regulation of
the targeting motif inclusion of BAG6 likely reflects the
distribution of its numerous interactors and functions
in the different tissue types. In general, the genes with
alternative motifs displaying a wide range of MII values
across tissues have many interactors and/or annotated
functions, many being kinases (10 with alternative NLS,
8 with alternative NES) or phosphatases (4 with alter-























































Number of transcripts per gene
Fig. 5 Number of motifs regulated by the different pre-translational regulation modes. Of the 175 NLSs considered, 68 are constitutive. The 107
alternatively regulated NLSs are classified with respect to 4 modes of regulation in panel a (left): direct alternative splicing of the encoding exon,
differential translation initiation, differential translation termination and frameshift. Similarly, of the 120 NESs considered, 34 are constitutive and
panel a (right) shows the regulation types of the 86 alternative NESs. Alternatively regulated NLSs and NESs are present in genes producing
significantly more transcripts than constitutive NLSs and NESs as shown in b (NLS on the left panel and NES on the right)
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Co-regulation of NLS and NES
Of the 45 genes encoding both an NLS and an NES and
detected in the Human Body Map project, the majority
(>75 %) are annotated as nuclear and cytoplasmic accord-
ing to Uniprot, several shuttling between these compart-
ments. As described in Fig. 8a, of these genes, 27 % (12/45)
have both a constitutive NLS and a constitutive NES (for
example FOXO3 in Fig. 8b) while 56 % (25/45) have an
NLS and an NES that are both alternative (for example
FHL1 and MIER1 in Fig. 8b), showing concordance in the
pre-translational regulation of these motifs (p-value =
7.0*10−5 by Fisher’s exact test). Amongst the 25 genes with
both an alternative NLS and alternative NES, 32 % (8/25)
show complete co-regulation of their alternative NLS and
NES, encoding the motifs in the same or co-regulated







Fig. 6 Heatmap representing the level of motif inclusion for alternative NLSs. The Human Body map project RNA-seq data was used to calculate
MII values for NLS motifs in each tissue considered. Only alternatively regulated motifs present in at least 9 of the 16 tissues considered are represented
here. MII values are represented using the color scheme depicted in the legend. Genes which were detected below a threshold of 1 TPM are represented
by grey cells in the heatmap
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tissues (MII going from to 0.016 in the heart to 0.88 in
white blood cells for both the NLS and NES), in any given
tissue, the MIIs of FHL1 are the same for its NLS and its
NES (Fig. 8b). FHL1 (Four and a Half LIM domains pro-
tein 1), also referred to as SLIM1 [53], is an ion channel
binding protein involved in cell differentiation and organ
morphogenesis, primarily found in the cytoplasm and par-
ticularly, at focal adhesions at the plasma membrane ac-
cording to Uniprot [47] and the HPA [44]. Both its NLS
and NES are encoded in a cassette exon which is only
included in two of the 14 coding transcripts produced by
the gene (Fig. 3b). By co-regulating its NLS and NES, such
a gene ensures that the encoded proteins will either be
solely cytoplasmic (absence of both the NLS and NES,
which is most often the case for FHL1), or capable of local-
izing to both the cytoplasm and nucleus, and cycling be-
tween them. A little under half of genes encoding both an
NLS and NES ensure the complete co-occurrence of these








Fig. 7 Heatmap representing the level of motif inclusion for alternative NESs. As for Fig. 6, the Human Body map project RNA-seq data was used
to calculate MII values for NES motifs in each tissue considered. Only alternatively regulated motifs present in at least 9 of the 16 tissues considered are
represented here. Motifs of same type present in the same gene and displaying the exact same MII profile across all tissues were collapsed into one entry
(for example, BRCA1 has two annotated NESs with the same MII profile across all tissues. These motifs were collapsed into one entry labelled BRCA1(1;2))



















































Fig. 8 Co-regulation of NLS and NES. 45 genes encoding both an NLS and NES were detected by RNA-seq in the Human Body Map project. The
distribution of their regulation types are shown in panel a, with both motifs being constitutive or both being alternative as the most abundant
groups. The distribution of motif inclusion for both the NLS and NES in a subset of these genes is shown in panel b. FOXO3 represents a gene
with both constitutive NLS and constitutive NES. FHL1 represents the group of genes with co-regulated but alternative NLS and NES. MIER1 and
RIPK3 have differentially regulated NLS and NES, with MIER1 showing high prevalence of NLS and low presence of NES while RIPK3 has a constitutive
NES and an alternative and variably present NLS
Luce et al. BMC Genomics  (2016) 17:472 Page 11 of 16
Of the remaining 56 % of genes containing both an
NLS and NES, but with less or no coordinated occur-
rence of the motifs (for example MIER1 and RIPK3 in
Fig. 8b), the majority show a preference for one of the
two motifs across all tissues. For example, the MIER1 NLS
is much more prevalent than its NES, while in RIPK3, the
NES is always present but the NLS can have a MII as low
as 0.39. MIER1 (mesoderm induction early response pro-
tein 1) proteins are transcriptional corepressors known to
function in the nucleus, although some have been detected
in the cytoplasm [54]. Alternative splicing and alternative
translation initiation sites result in proteins differing in the
presence of their NLS and/or NES [55] (as shown in
Figs. 3d, 4b). The uniformly high NLS MII and low NES
MII that we observe (Fig. 8b) are consistent the mainly nu-
clear role of the protein in normal tissues. In contrast, al-
though known to be capable of translocating to the nucleus
during necroptosis [56], RIPK3 is annotated as mainly func-
tioning in the cytoplasm, propagating the signal from the
tumor necrosis factor receptor by phosphorylating its sub-
strates [57, 58], consistent with the presence of a constitu-
tive NES and an alternative NLS. In general, many of the
genes encoding both an NLS and NES that are not co-
regulated encode proteins that have either large numbers of
interactors and diverse functions, including for example
PRKD2, SENP2 and KANK1, or have many isoforms anno-
tated as localized in diverse and different compartments
(for example MIER1 and PRKD2). Most of these regulate
the presence of these motifs in a tissue-specific manner,
some displaying switches between a strong presence of the
motif (MII near 1) and a near absence (MII near 0) of one
of their motifs between different tissues. A small number of
patterns of motif inclusion are predominantly used by the
cell, and represent tightly controlled programs.
Quantitative analysis of motif inclusion across a panel of
breast cancer tissues
As done for the Human body map RNA-seq datasets, the
motif inclusion of NLS and NES was quantified across a
panel of breast cancer datasets comparing estrogen-positive
tumors (ER+), triple negative tumors, HER2-positive tu-
mors (HER2+) and benign tumors [59] (Additional file 4:
Figures S2–S3). Once again, amongst the alternative motifs,
a subset of genes display strongly included or strongly ex-
cluded NLSs and NESs, with high overlap and same general
distribution with the equivalent subsets in the Human Body
Map datasets. Despite these general trends, cancer type
specific patterns also emerge. For example, the benign
breast cancer samples generally cluster separately from the
ER+, triple negative and HER2+ breast tumors, in particular
for the NLS heatmap, when looking at genes displaying
variable MII values, indicating that the inclusion of a subset
of these alternative motifs is differentially regulated between
benign cell lines and tumors. Such genes include CPSF6,
PABPN1, ARNTL, KANK1 and DST, which show striking
differences in the NLS MII when benign and non-benign
samples are compared (Additional file 4: Figure S2). While
some of these genes have been described as either strongly
mutated, deleted, deregulated or involved in pathways that
are deregulated in specific types of breast-cancer [60, 61],
their potential deregulation of localization has not been in-
vestigated. These results suggest that specific changes in
the inclusion of protein targeting motifs, as regulated at
pre-translational levels, might represent events specific to
certain tumor types, and could be used as novel bio-
markers. They might contribute to cancer phenotype and
their study could lead to insight into cancer maintenance
and progression.
Discussion and Conclusions
Timely regulation of protein subcellular localization is
crucial and underlies many cellular pathways. While pro-
tein localization can be controlled through several post-
translational mechanisms, cells also regulate protein
localization by varying the inclusion of targeting motifs at
pre-translational levels [32, 33, 37, 38]. Here, we describe
the extensive cellular use of these mechanisms for the
control of nucleo-cytoplasmic traffic through the study of
the inclusion of NLSs and NESs. The analysis of experi-
mentally validated human NLSs and NESs indicates that
these motifs are modular and that their inclusion is regu-
lated by the use of alternative promoter and/or translation
initiation, as previously described for signal peptides [35,
36], as well as by alternative splicing, by alternative trans-
lation termination, and also by coding frameshift for a
small number of genes. Alternative initiation and termin-
ation are the predominant mechanisms in use for this
regulation as was found for signal peptides and transmem-
brane domains [36]. The inclusion levels of these motifs,
as analyzed quantitatively using RNA-seq datasets, vary
from 0 to 100 %, depending on the gene and the tissue
type. While many NLSs and NESs are highly included
(most or all transcripts generated from the gene contain-
ing the motif), others are included at very low levels or at
variable levels which, for well characterized proteins, can
be explained by their molecular function. A majority of
these motifs are not present in a constitutive manner
(61 % of NLSs and 72 % of NESs are alternative) making
the pre-translational regulation of the inclusion of these
motifs a widely used mechanism in the regulation of pro-
tein cellular localization.
The pre-translational regulation of the inclusion of tar-
geting motifs is the first of several levels of regulation for
these localization signals. Subsequently, once included in
proteins, the accessibility of targeting motifs can be modu-
lated by interaction with other molecules or by allostery,
and can also be regulated by post-translational modifica-
tion [37]. In addition, the presence of different targeting
Luce et al. BMC Genomics  (2016) 17:472 Page 12 of 16
motifs within the same protein can lead to competition
between the motifs to determine the final localization.
These distinct levels of regulation serve different purposes
and exhibit different characteristics. While the regulation
of targeting motif accessibility is typically a reversible
regulation, the pre-translational regulation of their inclu-
sion is irreversible [37, 39], and thus the cell commits to
the level of motif inclusion it chooses, and has less flexibil-
ity for immediate responses requiring localization trans-
location. Nonetheless, this mode of regulation does
provide the possibility of co-regulation in the case of pro-
teins with significantly different sets of interactors de-
pending on their localization, as seems to be the case in
particular for some kinases shuttling between the nucleus
and cytoplasm. Thus the inclusion of specific targeting
motifs could be coordinated to occur when their sub-
strates/interactors present in the targeted compartment
are expressed, for example. The further characterization
of this widespread mechanism of regulation of protein
localization and the study of its use in combination with
post-translational regulation mechanisms will shed light
on and lead to better models of the regulation of this fun-
damental protein characteristic and the causes of its de-
regulation in disease states.
Methods
Data collation
Human NLSs and NESs were obtained from specialized
databases and by manual curation of the literature. 58
NLSs were obtained from the database of experimentally
validated localization signals LocSigDB [62] including 19
NLSs that are also present in NLSdb [63]. Many add-
itional NLSs were identified by manual curation of the
literature including 24 PY-NLSs described and listed in
[24]. To be included in the list, we required experimen-
tal validation including deletion/mutation analysis and
targeting of reporter proteins to the nucleus. 116 NESs
were obtained from the database of validated NESs
ValidNES [64] and 4 additional NESs by literature cur-
ation. References for all NLSs and NESs considered are
available in Additional file 1 as well as information re-
garding the database from which they were extracted
and a reference to the article in which their validation is
described. NLSs and NESs were only kept if they could
be mapped onto their corresponding encoding protein
and if their reported amino acid sequence did not exceed
50 amino acids in length [7], to ensure we are not work-
ing with signal patches.
Motif position analysis in exons and proteins
Transcripts and protein sequences, and their genomic
positions as well as exon positions were obtained from
the Ensembl database human genome build hg38, ver-
sion 82 [40]. No patches were applied. All data was
managed in an in house MySQL database. Motif se-
quences were mapped onto the encoding protein and
then onto the corresponding transcript and ultimately
onto the corresponding exon(s), by considering the pos-
ition of the start codon (coding start) and the positions
of all exons obtained from the Ensembl annotations
[40], allowing the evaluation of the number of exons in
which the motif is present. A sampling procedure ran-
domly choosing the same number of subsequences of
same length as NLSs or NESs from all proteins defined
in hg38 was used to evaluate the random distributions.
For the distribution of NLSs and NESs in protein se-
quences, the position of the first residue of the motif
was identified in the corresponding protein. The relative
position in the protein was obtained using the following
formula:
Relative motif position ¼ Pm= Lp‐Lm
 
where Pm is the position of the first residue of the motif
in the protein, Lp is the length of the protein and Lm is
the length of the motif.
The relative motif positions were then binned and the
resulting counts represented as histograms. To ensure
equal representation of genes regardless of the number of
isoforms encoded, each gene was given an equal weight in
the counts. As genes can code for different isoforms that
do not all encode the motif at the same position in the
resulting proteins, each coding isoform encoding the motif
was considered and given a partial count for the gene, the
total count for the gene totaling 1.
Classification of NLSs
NLSs were classified according to their type using the
following criteria:
– Bipartite NLSs were defined as those matching the
PDOC00015 prosite profile (two adjacent basic
amino acids (Arg or Lys), a spacer region of any 10
residues, at least three basic residues (Arg or Lys) in
the five positions after the spacer region) [65].
– Monopartite NLSs were required to conform to the
consensus sequence K(K/R)X(K/R) defined in [20].
– PY-NLSs were defined in the paper [24].
– All remaining NLSs were annotated as non-classified
with respect to their subtype.
Mode of pre-translational regulation of motif inclusion
A custom track specifying the positions of all NLSs and
NESs was generated for visualization with the UCSC
Genome Browser by considering the relative position of
the motif in the protein sequence, the absolute position
of the coding start of the transcript in the hg38 genome
build and the absolute positions of the exons of the
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transcripts in the hg38 genome build. Constitutive mo-
tifs were defined as motifs present in all coding tran-
scripts of a gene. In contrast, motifs are considered
alternative if there exists at least one coding transcript
of the encoding gene that does not contain the motif.
Motifs were classified according to the types of pre-
translational regulation modulating their inclusion (as
defined in Fig. 1) by considering all coding transcripts of
the encoding genes using in house scripts. Motifs are
considered absent from a transcript if their sequence
(according to Additional file 1) is not entirely included
in an isoform.
Quantification of motif inclusion by RNA-seq
To quantitatively determine the relative abundance of
the transcripts containing the motif compared to the
other transcripts of the same gene, we analyzed high-
throughput sequencing datasets of 16 different normal
human tissues from the Illumina Human Body Map Pro-
ject (NCBI GEO accession GSE30611). The RNA-seq
datasets for the 16 tissues consisted of between 74 and
82 million paired-end reads. The sra-toolkit was used to
extract the fastq files from the sra archived datasets [66]
using the fastq-dump command with split-files option.
Reads were aligned to the hg38 assembly of the human
genome, and quantified per transcript using Kallisto,
with the command line kallisto index –k21 [67].
The proportion of transcripts containing a motif of
interest out of all transcripts produced from a gene is re-
ferred to as the motif inclusion index (MII):






where N represents the set of all coding transcripts
encoded by gene g, K represents the set of all coding tran-
scripts encoded by gene g and containing motif m (K ⊆N)
and A represents a transcript’s relative abundance in TPM.
The MII values were only calculated for genes with a total
abundance of above 1 TPM for a given dataset.
The GSE45419 datasets consisting of benign breast le-
sions, ER positive, triple negative and HER2 positive pri-
mary breast tumors [59] were analyzed in the same way
as the Human Body Map Project datasets as described
above.
Additional files
Additional file 1: Experimentally validated NLS and NES motifs considered
in this study, with their sequence and reference. (PDF 341 kb)
Additional file 2: Classification of all NLS motifs considered in this
study, including their sequence, class, regulation modes, number of
encoding transcripts and number of encoding exons. (XLSX 23 kb)
Additional file 3: Classification of all NES motifs considered in this
study, including their sequence, regulation modes, number of encoding
transcripts and number of encoding exons. (XLSX 15 kb)
Additional file 4: Figure S1. Characteristics of NLS subtypes. NLSs were
classified according to their type as described in the Methods. The number
of NLSs of different subtype with the indicated characteristics are shown.
Figure S2. Heatmap representing the level of motif inclusion for alternative
NLSs. The GSE45419 RNA-seq datasets consisting of benign breast lesions,
ER positive, triple negative and HER2 positive primary breast tumors (32
samples in total) were analyzed to quantify the NLS MII in each tissue
considered. MII values are represented using the color scheme depicted in the
legend. Genes which were detected below a threshold of 1 TPM were
not further considered and are represented by grey cells in the heatmap.
Only motifs present in at least 17 of the 32 samples are shown. The sample
type is indicated using a color-coded bar at the top of the heatmap. While
some NLSs display generally uniform MII values across the samples regardless
of type, a subset show specificity for a certain sample type. In particular, the
benign breast lesions cluster together and display different MII values for
some NLSs, suggesting a differential regulation of the presence of the NLS in
these samples. Figure S3. Heatmap representing the level of motif inclusion
for alternative NESs. As for figure S2, the GSE45419 RNA-seq datasets were
analyzed to quantify the NES MII in each tissue considered. The heatmap is as
described for figure S2. Motifs of same type present in the same gene and
displaying the exact same MII profile across all tissues were collapsed into
one entry (for example, CDC7 has two annotated NESs with the same MII
profile across all tissues. These motifs were collapsed into one entry labelled
CDC7(1;2)). (PDF 419 kb)
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